Sep 9 |
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
|
Aug 26 |
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
|
Aug 26 |
ImmunoPrecise Antibodies receives non-compliance notice from Nasdaq
|
Aug 24 |
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
|
Jul 30 |
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2024 Earnings Call Transcript
|
Jul 29 |
ImmunoPrecise reports Q4 results
|
Jul 29 |
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
|
Jul 17 |
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
|
Jul 15 |
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
|
Jun 27 |
ImmunoPrecise appoints Kristin Taylor as CFO
|